Hematology News

Antiplatelet agents such as aspirin may reduce the rate of vascular access thrombosis among hemodialysis patients, according to results of a retrospective cohort study published in the Journal of Thrombosis and Hemostasis.

Higher platelet transfusion threshold appeared to increase risk for death and major bleeding among preterm infants with severe thrombocytopenia, according to results of a randomized trial published in The New England Journal of Medicine.

Older age, smoking and obesity were consistently associated with increased risk for venous thromboembolism, according to a study published in JAMA Cardiology.

British women recently exposed to oral hormone therapy were 58% more likely to receive a primary diagnosis of venous thromboembolism than women not exposed to HT, with risk increasing for certain combined preparations, according to findings published in The BMJ.

Adipose-derived mesenchymal stem cell lines could be used to manufacture platelets that may serve as an alternative to donor-dependent platelet transfusions, according to research published in Blood.

The FDA granted breakthrough therapy designation to crizanlizumab for the prevention of vaso-occlusive crises among patients with sickle cell disease.

The addition of eltrombopag to standard immunosuppressive therapy did not have a significant impact on response rates or survival outcomes among patients with newly diagnosed severe aplastic anemia, according to results of an open-label phase 2 trial.

The FDA granted fast track designation to CTX001, a gene-edited hematopoietic stem cell therapy, for the treatment of sickle cell disease.

A real-time, targeted educational intervention for hospitalized patients led to fewer missed doses of venous thromboembolism prophylaxis, according to findings published in JAMA Network Open.

Portola Pharmaceuticals announced that the FDA approved its Prior Approval Supplement for the second generation of andexanet alfa, allowing for its broad commercial launch in the U.S.